keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy hematological

keyword
https://www.readbyqxmd.com/read/29444512/a-phase-ii-study-of-irinotecan-for-patients-with-previously-treated-small-cell-lung-cancer
#1
Rie Kondo, Satoshi Watanabe, Satoshi Shoji, Kosuke Ichikawa, Tetsuya Abe, Junko Baba, Junta Tanaka, Hiroki Tsukada, Masaki Terada, Kazuhiro Sato, Yoshie Maruyama, Masato Makino, Akira Hirata, Hiroshi Tanaka, Toshiyuki Koya, Hirohisa Yoshizawa, Toshiaki Kikuchi
OBJECTIVE: Chemotherapy with irinotecan plus cisplatin has shown promise in chemo-naïve small-cell lung cancer (SCLC) patients. However, irinotecan treatment for relapsed or refractory SCLC has not been adequately evaluated. This phase II study evaluated the appropriate treatment schedule of irinotecan as a single agent. This study was designed to determine the antitumor activity, toxicity, and survival in previously treated SCLC patients. METHODS: Previously treated SCLC patients with at least one platinum-based regimen received irinotecan (100 mg/m2) on days 1 and 8, every 3 weeks, until disease progression...
February 14, 2018: Oncology
https://www.readbyqxmd.com/read/29443792/pleural-cavity-cytokine-release-syndrome-in-cd19-directed-chimeric-antigen-receptor-modified-t-cell-therapy-a-case-report
#2
Lijuan Ding, Yongxian Hu, Kui Zhao, Guoqing Wei, Wenjun Wu, Zhao Wu, Lei Xiao, He Huang
RATIONALE: Cytokine release syndrome (CRS) is a common and potentially fatal complication of CAR-T cell therapy. However, compartment CRS is relatively rare in hematological malignancies, as well as in solid tumors. The pathogenesis and prognosis of compartment CRS are unclear and there is no standardized treatment yet. In this case report, we will introduce a patient developing pleural cavity CRS after CART19s infusion. PATIENT CONCERNS: A 28-year-old woman was admitted for evaluation of mediastinal mass...
February 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29443727/acute-bilateral-retina-hemorrhages-beneath-internal-limiting-membrane-an-unusual-ophthalmological-case-report-of-acute-leukemia-during-complete-clinical-remission
#3
Shuyuan Lyu, Ming Zhang, Yunxia Gao
RATIONALE: Leukemia is a common hematologic disease that causes various systemic complications, such as ophthalmological disorders. The venous congestion is considered to be the main clinical sign that occurs during the initial stage of the disease, whereas white-centered hemorrhages are the most typical manifestations in leukemic retinopathy. These complications usually manifest when the disease presents with clinical and hematological symptoms. In the present study, we report a patient who was diagnosed with leukemic retinopathy...
February 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29440919/efficacy-and-safety-of-cox-2-inhibitors-for-advanced-non-small-cell-lung-cancer-with-chemotherapy-a-meta-analysis
#4
Ping Dai, Jing Li, Xiao-Ping Ma, Jian Huang, Juan-Juan Meng, Ping Gong
Background: The study of cyclooxygenase-2 (COX-2) inhibitors is now mired in controversy. We performed a meta-analysis to assess the efficacy and safety profile of COX-2 inhibitors in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: A literature search of PubMed, EMBASE, the Cochrane Central databases, and ClinicalTrials.gov, up until March 26, 2017, identified relevant randomized controlled trials. Data analysis was performed using Stata 12...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29439419/immunoconjugates-for-osteosarcoma-therapy-preclinical-experiences-and-future-perspectives
#5
REVIEW
Daniele Mercatelli, Massimo Bortolotti, Alberto Bazzocchi, Andrea Bolognesi, Letizia Polito
Osteosarcoma (OS) is an aggressive osteoid-producing tumor of mesenchymal origin, which represents the most common primary bone malignancy. It is characterized by a complex and frequently uncertain etiology. The current standard care for high-grade OS treatment is neoadjuvant chemotherapy, followed by surgery and post-operative chemotherapy. In order to ameliorate survival rates of patients, new therapeutic approaches have been evaluated, mainly immunotherapy with antibody-drug conjugates or immunoconjugates...
February 10, 2018: Biomedicines
https://www.readbyqxmd.com/read/29435730/bi-weekly-eribulin-therapy-for-metastatic-breast-cancer-a-multicenter-phase-ii-prospective-study-just-study
#6
Shoichiro Ohtani, Takahiro Nakayama, Tetsuhiro Yoshinami, Ken-Ichi Watanabe, Fumikata Hara, Yasuaki Sagara, Hidetoshi Kawaguchi, Kenji Higaki, Nobuki Matsunami, Yoshie Hasegawa, Masato Takahashi, Makiko Mizutani, Takashi Morimoto, Masako Sato, Mitsuya Itoh, Satoshi Morita, Norikazu Masuda
BACKGROUND: This study aimed to investigate whether schedule modification is safe and effective in patients intolerant to the standard eribulin dose and schedule. METHODS: Patients with metastatic breast cancer (MBC) treated with both anthracycline and taxane and ≤ 3 prior regimens of chemotherapy for MBC received eribulin at the standard dose and schedule (1.4 mg/m2 on days 1 and 8 of a 21-day cycle) in the first cycle; change of dosing schedule (1.4 mg/m2 on days 1 and 15 of a 28-day cycle) was determined by change in neutrophil count, platelet count, aspartate aminotransferase, alanine aminotransferase, total bilirubin, serum creatinine, and non-hematological toxicity on day 8 of the first cycle or day 1 of the second cycle...
February 12, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29435025/bromelain-has-significant-clinical-benefits-after-extraction-of-the-third-molar-during-chemotherapy-in-patients-with-hematologic-tumor
#7
Yi Tan, Ping Li
The purpose of this study was to investigate the application of bromelain in the treatment of pain, swelling, and limited mouth opening in patients with hematologic tumor after extraction of the third molar during chemotherapy. We recruited 72 patients with hematologic tumor who were treated by oral and maxillofacial surgery in our hospital, and third molar extraction was performed under local anesthesia. After extraction, patients in the control group were treated with cold - hot compress and patients in the experimental group were treated by oral administration of bromelain...
March 2018: Oncology Letters
https://www.readbyqxmd.com/read/29430988/protective-effect-of-d-methionine-on-body-weight-loss-anorexia-and-nephrotoxicity-in-cisplatin-induced-chronic-toxicity-in-rats
#8
Ming-Tai Lin, Jiunn-Liang Ko, Te-Chung Liu, Pei-Tsen Chao, Chu-Chyn Ou
D-methionine is a sulfur-containing amino acid that can act as a potent antioxidant. Anorexia and nephrotoxicity are side effects of cisplatin. The protective effects of D-methionine on cisplatin-induced anorexia and renal injury were investigated. The model of chronic cisplatin administration (5 mg/kg body weight) involved intraperitoneal injection on days 1, 8, and 15 and oral D-methionine (300 mg/kg body weight) coadministration daily for 20 days. On the 21st day of treatment, food intake and body weight in the cisplatin-treated group significantly decreased by 52% and 31%, respectively, when compared with a control group...
February 1, 2018: Integrative Cancer Therapies
https://www.readbyqxmd.com/read/29428267/disseminated-cerebral-toxoplasmosis-in-a-patient-with-chronic-lymphocytic-leukemia
#9
Jordan Xu, Rod J Nault, Andres Maldonado-Naranjo, Leonardo A Frizon, Kuruvilla John, Katherine Holman, Sean J Nagel
Infections are one of the most common causes of mortality in immunocompromised patients. In patients diagnosed with hematologic malignancies, treatment with stem cell transplants (SCT) or T-cell suppressing chemotherapy increases the risk of central nervous system (CNS) infections, of which toxoplasmosis is the most common. We report the case of a 63 year-old woman with chronic lymphocytic leukemia (CLL) that presented with gait instability and visual changes. Intracranial lesions were noted on initial neuro-imaging...
February 7, 2018: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/29424411/-blastic-plasmacytoid-dendritic-cell-neoplasm-report-of-three-cases
#10
Alejandro Avilés-Salas, Myrna Candelaria, Mayra Ponce, Abraham Cañavera-Constantino, Sebastián Burgos
Blastic plasmacytoid dendritic cell neoplasm is a rare hematological malignancy derived from immature plasmacytoid dendritic cells. The tumor cells have an immature blastic appearance, and diagnosis is based on the expression of CD4, CD56 y CD123 in the absence of other lymphoid, natural killer, or myeloid antigens. The majority of affected individuals are older people with a mean age of 66 years. Male to female ratio is approximately 3:1. Common presentation includes cutaneous lesions followed by tumor dissemination...
September 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/29423520/cisplatin-chemoradiotherapy-vs-radiotherapy-in-figo-stage-iiib-squamous-cell-carcinoma-of-the-uterine-cervix-a-randomized-clinical-trial
#11
Shyamkishore Shrivastava, Umesh Mahantshetty, Reena Engineer, Supriya Chopra, Rohini Hawaldar, Vinod Hande, Rajendra A Kerkar, Amita Maheshwari, T S Shylasree, Jaya Ghosh, Jyoti Bajpai, Lavanya Gurram, Seema Gulia, Sudeep Gupta
Importance: The evidence for concurrent chemoradiotherapy (CT-RT) in International Federation of Gynecology and Obstetrics (FIGO) stage IIIB squamous cell carcinoma of the uterine cervix is not robust. This study reports the final results of a randomized clinical trial of concurrent cisplatin-based CT-RT and radiotherapy alone (RT) in women with FIGO stage IIIB squamous cell carcinoma of the uterine cervix. Objective: To investigate the benefit of concurrent CT-RT in FIGO stage IIIB squamous cell carcinoma of the uterine cervix...
February 8, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29423222/clinicopathological-characteristics-of-disseminated-carcinomatosis-of-the-bone-marrow-in-breast-cancer-patients
#12
Yoshiaki Shinden, Keishi Sugimachi, Fumiaki Tanaka, Kenji Fujiyoshi, Yuko Kijima, Shoji Natsugoe, Koshi Mimori
Disseminated carcinomatosis of the bone marrow (DCBM) is characterized by diffuse infiltrative growth of tumor cells in the bone marrow and is associated with systemic hematological disorders. Bone marrow metastases from breast cancer are not rare, and they may lead to serious life-threatening conditions when there is an associated hematological disorder. Therefore, DCBM necessitates a definitive diagnosis and prompt systemic therapy. We herein present 4 such cases and a review of the previous relevant literature...
January 2018: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29420340/phase-i-trial-of-belinostat-with-cisplatin-and-etoposide-in-advanced-solid-tumors-with-a-focus-on-neuroendocrine-and-small-cell-cancers-of-the-lung
#13
Sanjeeve Balasubramaniam, Christophe E Redon, Cody J Peer, Christine Bryla, Min-Jung Lee, Jane B Trepel, Yusuke Tomita, Arun Rajan, Giuseppe Giaccone, William M Bonner, William D Figg, Tito Fojo, Richard L Piekarz, Susan E Bates
The standard-of-care for advanced small cell lung cancer (SCLC) is chemotherapy with cisplatin+etoposide (C+E). Most patients have chemosensitive disease at the outset, but disease frequently relapses and limits survival. Efforts to improve therapeutic outcomes in SCLC and other neuroendocrine cancers have focused on epigenetic agents, including the histone deacetylase inhibitor belinostat. The primary objective was to determine the maximum tolerated dose of the combination of belinostat (B) with C+E. Belinostat was administered as a 48-h continuous intravenous infusion on days 1-2; cisplatin was administered as a 1-h intravenous infusion on day 2; and etoposide was administered as a 1-h intravenous infusion on days 2, 3, and 4...
February 7, 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29419687/synchronous-papillary-thyroid-cancer-and-non-hodgkin-lymphoma-case-report
#14
Georgi I Popivanov, Pavel Bochev, Radka Hristoskova, Ventsislav M Mutafchiyski, Mihail Tabakov, Anthony Philipov, Roberto Cirocchi
RATIONALE: Differentiated thyroid cancer is the most common endocrine malignancy with concomitant hematological malignancy in 7%. PATIENT CONCERNS: We present a case of a synchronous papillary thyroid cancer and a follicular variant of non-Hodgkin lymphoma and discuss the possible diagnostic and treatment dilemmas. DIAGNOSIS: A 48-year-old female was reffered to our hospital with diagnosis "thyroid cancer". Due to a history compatable of synchronous lymphoproliferative disease we performed a computed tomography, which revealed multiple enlarged lymph nodes in the neck, mediastinum, axilla and abdomen...
February 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29418009/multidisciplinary-approach-in-a-case-of-hand-sch%C3%A3-ller-christian-disease-with-maxillary-involvement
#15
Angela Pia Cazzolla, Nunzio Francesco Testa, Gianfranco Favia, Maria Grazia Lacaita, Domenico Ciavarella, Khrystyna Zhurakivska, Giuseppe Troiano, Lorenzo Lo Muzio
Langerhans cell histiocytosis (LCH) is a childhood pathology with a peak of incidence ranging from 1 to 4 years of age, though diagnosis is often made in adult age. LCH is clinically classified into three types: eosinophilic granuloma, Hand-Schuller-Christian disease and Abt-Letterer-Siwe disease. We report a case of Hand-Schüller-Christian disease with diabetes insipidus, skull and maxillary involvement in a 16-year-old boy referred to our observation for gradual increase in mobility of the teeth and subsequent gradual loss of the second premolars and the first molars of the upper jaw...
February 8, 2018: Special Care in Dentistry
https://www.readbyqxmd.com/read/29416770/hprt1-activity-loss-is-associated-with-resistance-to-thiopurine-in-all
#16
Fan Yang, Houshun Fang, Dan Wang, Yao Chen, Yonggong Zhai, Bin-Bing S Zhou, Hui Li
Acute lymphoblastic leukemia (ALL) is an aggressive hematological tumor resulting from the malignant transformation of lymphoid progenitors. Thiopurine is a widely used drug in the maintaining treatment of ALL. After a period of chemotherapy, 20% of pediatric patients and over 50% of adult patients will relapse. To investigate the mechanisms of drug resistance in vitro, we established the thiopurine resistant cell lines Reh-6MPR (6-MP Resistant cell) and Reh-6TGR (6-TG Resistant cell) by stepwise selection of the ALL cell line Reh...
January 5, 2018: Oncotarget
https://www.readbyqxmd.com/read/29416753/co-targeting-of-tiam1-rac1-and-notch-ameliorates-chemoresistance-against-doxorubicin-in-a-biomimetic-3d-lymphoma-model
#17
Muhammad Ikram, Yeseon Lim, Sun-Yong Baek, Songwan Jin, Young Hun Jeong, Jong-Young Kwak, Sik Yoon
Lymphoma is a heterogeneous disease with a highly variable clinical course and prognosis. Improving the prognosis for patients with relapsed and treatment-resistant lymphoma remains challenging. Current in vitro drug testing models based on 2D cell culture lack natural tissue-like structural organization and result in disappointing clinical outcomes. The development of efficient drug testing models using 3D cell culture that more accurately reflects in vivo behaviors is vital. Our aim was to establish an in vitro 3D lymphoma model that can imitate the in vivo 3D lymphoma microenvironment...
January 5, 2018: Oncotarget
https://www.readbyqxmd.com/read/29416652/phase-ii-study-of-rituximab-given-in-conjunction-with-standard-chemotherapy-in-primary-central-nervous-system-lymphoma-pcnsl-a-trial-of-the-ecog-acrin-cancer-research-group-e1f05
#18
Lode J Swinnen, Anne O'Neill, Philip H Imus, Sachin Gujar, David Schiff, Lawrence R Kleinberg, Ranjana H Advani, Erin M Dunbar, Dennis Moore, Stuart A Grossman
Background: Therapy of primary CNS lymphoma (PCNSL) has focused on multi-agent chemotherapy designed to cross the blood brain barrier. Rituximab has demonstrated activity in PCNSL. E1F05 is an ECOG-ACRIN multicenter phase 2 prospective trial of rituximab with high-dose methotrexate (HD-MTX)-based chemotherapy similar to the RTOG 93-10 regimen, omitting radiotherapy. Methods: Immunocompetent patients with newly diagnosed PCNSL received HD-MTX 3.5g/m2 with vincristine every two weeks for 5 doses; procarbazine for 7 days in weeks 1, 5, and 9; cytarabine 3g/m2/day IV for 2 days in weeks 11 and 14; a dexamethasone taper over 6 weeks; and rituximab 375mg/m2 IV infusion 3 times per week for weeks 1-4...
January 2, 2018: Oncotarget
https://www.readbyqxmd.com/read/29416363/liver-fungal-infections-an-overview-of-the-etiology-and-epidemiology-in-patients-affected-or-not-affected-by-oncohematologic-malignancies
#19
REVIEW
Marco Fiore, Marco Cascella, Sabrina Bimonte, Alberto Enrico Maraolo, Ivan Gentile, Vincenzo Schiavone, Maria Caterina Pace
Fungal infections of the liver, most commonly caused by Candida spp., often occur in patients with hematologic malignancies treated with chemotherapy. Colonization of the gastrointestinal tract is thought to be the main origin of dissemination of Candida; mucositis and neutropenia facilitate the spread of Candida from the gastrointestinal tract to the liver. Hepatic involvement due to other fungi is a less common infectious complication in this setting. Fungal infections represent a less common cause of hepatic abscesses in non-oncohematologic population and the trend appears to be decreasing in recent years...
2018: Infection and Drug Resistance
https://www.readbyqxmd.com/read/29415584/management-of-chronic-viral-hepatitis-in-the-hematological-patient
#20
Laura Ambra Nicolini, Emanuela Zappulo, Claudio Viscoli, Malgorzata Mikulska
Infection with HBV and HCV represents a growing challenge in the management of patients with hematological malignancies. Recently, hepatitis E (HEV) was recognized as an endemic infection in developed countries and as an emerging health problem in immunocompromised patients. Areas covered: We reviewed the current knowledge on the impact of chronic viral hepatitis in the hematological setting. Epidemiological features, screening strategies and indications for treatment and monitoring have been explored and commented...
February 8, 2018: Expert Review of Anti-infective Therapy
keyword
keyword
69738
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"